Constantine C Alifrangis

Learn More
BRAF (v-raf murine sarcoma viral oncogene homolog B) inhibitors elicit a transient anti-tumor response in ∼ 80% of BRAF(V600)-mutant melanoma patients that almost uniformly precedes the emergence of resistance. Here we used a mouse model of melanoma in which melanocyte-specific expression of Braf(V618E) (analogous to the human BRAF(V600E) mutation) led to(More)
A major challenge in cancer genetics is to determine which low-frequency somatic mutations are drivers of tumorigenesis. Here we interrogate the genomes of 7,651 diverse human cancers and find inactivating mutations in the homeodomain transcription factor gene CUX1 (cut-like homeobox 1) in ~1-5% of various tumors. Meta-analysis of CUX1 mutational status in(More)
Trametinib NF1 BRAF NRAS WT WT WT V600E WT WT WT WT neg pos pos pos Colo-792 C037 A04 C089 Cell line ID Supplementary Figure 3. Trametinib induced pERK downregulation in melanoma cell lines independent of their BRAF/NRAS and NF1 status. Treatment with trametinib 5nM for 6h induces downregulated pERK in BRAF/NRAS wild type NF1 positive cell lines, and in(More)
Langerhans cell histiocytosis (LCH) has been previously thought of as a rare illness, but is now increasingly diagnosed as a result of the more intensive investigations of patients with cystic pulmonary disease. In recent years, treatments developed from our new understanding of the molecular biology of malignant disease have been applied to patients with(More)
PURPOSE Patients with high-risk (International Federation of Gynecology and Obstetrics score ≥ 7) gestational trophoblastic neoplasia (GTN) frequently receive etoposide, methotrexate, and dactinomycin alternating weekly with cyclophosphamide and vincristine (EMA/CO). Between 1979 and 1995, overall survival (OS) with this regimen at our institute was 85.4%(More)
OBJECTIVES To assess the needs of cancer patients for information about their condition and to understand the psychological impact of their illness. BACKGROUND The discussion of prognosis and treatment options in the palliative setting is an important and difficult part of oncology practice. To evaluate this, we examined the experiences of cancer patients(More)
AIMS Studies of circulating tumor cells (CTCs) have generally recruited individuals with newly diagnosed metastatic cancer, with recent data also indicating their prognostic value in the adjuvant setting. Their role in dying patients has not been established. EXPERIMENTAL CTCs were measured in 43 individuals with metastatic breast cancer estimated to have(More)
Following the fanfare of initial, often dramatic, success with small molecule inhibitors in the treatment of defined genomic subgroups, it can be argued that the extension of targeted therapeutics to the majority of patients with solid cancers has stalled. Despite encouraging FDA approval rates, the attrition rates of these compounds remains high in early(More)
Gestational trophoblastic disease is a spectrum of disorders ranging from premalignant hydatidiform moles through to malignant invasive moles, choriocarcinoma and rare placental site trophoblastic tumor. The latter are often collectively referred to as gestational trophoblastic tumors or neoplasia (GTN). Although most women can expect to be cured of their(More)